SCHEMBL5534569

SCHEMBL5534569

CCOc1ccc2scc(C)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.55
MAPT P10636 5/20 0.55
HSD17B10 Q99714 5/20 0.55
CYP2A6 P11509 1/20 0.51
KDM4E B2RXH2 7/20 0.45
HPGD P15428 4/20 0.45
NPC1 O15118 3/20 0.44
RAB9A P51151 2/20 0.44
TP53 P04637 2/20 0.44
NQO1 P15559 1/20 0.43
ALOX12 P18054 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KMT2A Q03164 4/20 0.42
TSHR P16473 3/20 0.42
MEN1 O00255 3/20 0.42
PARP15 Q460N3 1/20 0.41
PARP10 Q53GL7 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
MTNR1A P48039 1/20 0.41
PSMB8 P28062 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544027 0.86 ALDH1A1 (0.69) ALDH1A1MAPTHSD17B10CYP2A6KDM4E
SCHEMBL3480209 0.82 CYP2A6 (0.51) ALDH1A1MAPTHSD17B10CYP2A6MTNR1A
SCHEMBL5544022 0.81 ALDH1A1 (0.54) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL788146 0.80 CYP2A6 (0.56) ALDH1A1MAPTHSD17B10CYP2A6KDM4E
SCHEMBL5542145 0.75 CYP2A6 (0.50) HSD17B10CYP2A6KDM4ENPC1RAB9A
SCHEMBL5544002 0.72 ALDH1A1 (0.47) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL9215496 0.72 ALDH1A1 (0.48) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL423281 0.71 CYP2A6 (0.64) ALDH1A1MAPTCYP2A6TP53CYP1A2
SCHEMBL5534567 0.71 MAPT (0.67) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL10852352 0.71 HCRTR1 (0.54) ALDH1A1MAPTHSD17B10CYP2A6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885MAPT 4117/4885HSD17B10 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.